NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
TRIJARDY XR (empagliflozin, linagliptin, metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2020.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIJARDY XR is a triple-combination oral tablet containing empagliflozin (SGLT2 inhibitor), linagliptin (DPP-4 inhibitor), and metformin hydrochloride (biguanide) in extended-release formulation. It is indicated for type 2 diabetes mellitus in adults to improve glycemic control. The combination works through three complementary mechanisms: reducing glucose reabsorption in the kidneys, enhancing incretin-mediated insulin secretion, and decreasing hepatic glucose production.
$76MPart D
PeakStable
11.1 years to LOEProduct is in peak lifecycle stage with $76M annual spending, indicating stable market position but limited expansion headroom; brand teams should focus on market penetration and defensive positioning.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRIJARDY XR offers exposure to Boehringer Ingelheim's flagship diabetes franchise during a stable, mature market phase; career value lies in defensive market strategy, competitive positioning, and optimizing penetration within an established indication. Professionals should anticipate shift toward LOE planning and post-exclusivity strategy development within the next 5 years.
Brand Manager
Worked on TRIJARDY XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.